**Table S1. Demographic and clinicopathological characteristics of cases by EC molecular subtype**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **MSS** | **MSI** | ***POLE*** | **Total** |
| **PORTEC, LUMC & UMCG series** |  |  |  |
| Age |  |  |  |  |
| Median | 62.5 | 68.8 | 63.5 | 65.0 |
| Range | 36-84 | 35-89 | 46-82 | 35-89 |
| FIGO stage (2009) |  |  |  |  |
| I/II | 48 | 39 | 45 | 132 |
| III/IV | 6 | 10 | 2 | 18 |
| Grade |  |  |  |  |
| 1/2 | 45 | 39 | 33 | 117 |
| 3 | 9 | 10 | 14 | 33 |
| Type |  |  |  |  |
| EEC | 54 | 49 | 47 | 150 |
| NEEC | 0 | 0 | 0 | 0 |
| Total | 54 | 49 | 47 | 150 |
|  |  |  |  |  |
| **TCGA series** |  |  |  |  |
| Age |  |  |  |  |
| Median | 64 | 63 | 57 | 63 |
| Range | 34-90 | 35-88 | 33-87 | 33-90 |
| FIGO stage (2009) |  |  |  |  |
| I/II | 116 | 57 | 14 | 187 |
| III/IV | 40 | 12 | 4 | 56 |
| Unknown | 1 | 1 | 0 | 2 |
| Grade |  |  |  |  |
| 1/2 | 97 | 45 | 9 | 151 |
| 3 | 60 | 24 | 9 | 93 |
| Type |  |  |  |  |
| EEC | 114 | 69 | 18 | 201 |
| NEEC | 43 | 0 | 0 | 43 |
| Total | 157 | 69 | 18 | 244 |
|  |

MSS – microsatellite stable, *POLE* wild-type; MSI – microsatellite unstable, *POLE* wild-type; *POLE* – *POLE* proofreading mutant; EEC – endometrioid endometrial cancer; NEEC – non-endometrioid endometrial cancer

Note: (i) TCGA analysis excludes one NEEC for which MSI status could not be determined. (ii) all *POLE*-proofreading mutant ECs were MSS with exception of one TCGA tumor (TCGA-AP-A051) which was assigned to the *POLE*-mutant subgroup on basis of characteristic mutation signature